Skip to main content Skip to section navigation Skip to footer
News & Media Careers Contact
Carrick Therapeutics Limited
  • Home
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors & Observers
    • Collaborators & Advisors
  • Science
    • Overview
    • Posters & Publications
  • Pipeline
    • Overview
    • CDK7 Inhibitor
    • CDK12/13 Inhibitor
  • Partnering
  • News & Media
  • Careers
  • Contact

Press Releases

News & Media

News & Media

  • Overview
  • Press Releases
  • IR Calendar
  • In The News
  • Posters & Publications
Jun 28, 2019 2:00am EDT

Carrick Therapeutics - Establishment of US operations and new CEO

Oct 11, 2018 2:00am EDT

Carrick Therapeutics In-Licenses Targeted Ovarian Cancer Treatment From BTG and Appoints George Golumbeski as Chairman

Nov 30, 2017 2:00am EST

Carrick Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of its Oral CDK7 Inhibitor: CT7001

Oct 03, 2016 2:00am EDT

Launch of Carrick Therapeutics Signals New Approach to Cancer Therapies

  • Previous Pagearrow_back
  • Page 1
  • Page 2
rss_feed News RSS
©2023 Carrick Therapeutics Limited. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Visit us on Linkedin Manage Cookie Preferences